Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial
Narra X · 13.07.2026 · 4 (2) · e282
DOI: 10.52225/narrax.v4i2.282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Narra X, online erschienen am 13.07.2026. Verfasst von Maryatun Hasan und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Frailty is increasingly recognized among people living with human immunodeficiency virus (PLHIV) despite antiretroviral therapy (ART). Statins, including atorvastatin, have pleiotropic metabolic and anti-inflammatory effects that may influence frailty-related pathways, although their impact on frailty in PLHIV remains unclear. The aim of this study was to evaluate the effect of atorvastatin on frailty status, its components, body composition, and related laboratory parameters in PLHIV receiving ART. This randomized, double-blind, placebo-controlled clinical trial included PLHIV with frailty or pre-frailty status at baseline. Participants were assigned to receive atorvastatin 40 mg once daily or placebo for 12 weeks. The primary outcome was frailty incidence, assessed using Cardiovascular Health Study (CHS)-based criteria and the Frailty Index (FI), including combined CHS–FI frailty status and CHS-based frailty components. Secondary outcomes included body composition, total cholesterol, and serum myostatin levels. Statistical analyses were performed using unadjusted and adjusted models. After 12 weeks, FI scores improved significantly within both the placebo (p
Zitieren
APA
Hasan, M., Jamil, K. F., Darmawi, D., & Syukri, M. (2026). Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial. Narra X, 4(2), e282. https://doi.org/10.52225/narrax.v4i2.282
Vancouver
Hasan M, Jamil KF, Darmawi D, Syukri M. Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial. Narra X. 2026;4(2):e282. doi:10.52225/narrax.v4i2.282
BibTeX
@article{Hasan2026,
author = {Hasan, Maryatun and Jamil, Kurnia F. and Darmawi, Darmawi and Syukri, Maimun},
title = {Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial},
journal = {Narra X},
year = {2026},
volume = {4},
number = {2},
pages = {e282},
doi = {10.52225/narrax.v4i2.282}
}
EUVIMED